FluView: A Weekly Influenza Surveillance Report Prepared by the Influenza Division

2015-2016 Influenza Season Week 14 ending April 9, 2016

All data are preliminary and may change as more reports are received.


During week 14 (April 3-9, 2016), influenza activity decreased, but remained elevated in the United States.

National and Regional Summary of Select Surveillance Components

HHS Surveillance Regions* Data for current week Data cumulative since October 4, 2015 (week 40)
Out-patient ILI Number of jurisdictions experiencing high or moderate ILI activity§ % respiratory specimens positive for flu in clinical laboratories A(H1N1)pdm09 A (H3) A (Subtyping not Performed)
B Victoria lineage B Yamagata lineage B lineage not performed Pediatric Deaths
Influenza test results from public health laboratories only
Nation Elevated 3 of 53 14.0% 12,821 2,750 253 1,023 2,443 2,019 50
Region 1 Elevated 0 of 6 19.6% 1,056 82 5 59 38 144 3
Region 2 Elevated 2 of 4 21.2% 976 160 11 77 46 103 4
Region 3 Elevated 0 of 6 17.5% 2,000 110 40 183 253 97 2
Region 4 Elevated 0 of 8 15.2% 1,070 218 38 48 41 310 9
Region 5 Normal 0 of 6 15.1% 2,317 222 83 123 184 31 10
Region 6 Normal 0 of 5 14.2% 425 261 7 65 83 198 4
Region 7 Normal 0 of 4 8.7% 422 54 11 28 87 18 1
Region 8 Elevated 0 of 6 16.2% 1,620 327 5 92 462 81 1
Region 9 Normal 1 of 4 10.5% 2,153 1,189 42 287 881 759 15
Region 10 Elevated 0 of 4 21.0% 782 127 11 61 368 278 1

*HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, US Virgin Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, SC, TN; Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE; Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; and Region 10: AK, ID, OR, WA).
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline
§ Includes all 50 states, New York City, the District of Columbia and Puerto Rico
‡ National data are for current week; regional data are for the most recent three weeks

U.S. Virologic Surveillance:

WHO and NREVSS collaborating laboratories, which include both public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of Columbia, report to CDC the total number of respiratory specimens tested for influenza and the number positive for influenza by virus type. In addition, public health laboratories also report the influenza A subtype (H1 or H3) and influenza B lineage information of the viruses they test and the age or age group of the persons from whom the specimens were collected.

Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html.

The results of tests performed by clinical laboratories during the current week are summarized below.

  Week 14 Data Cumulative since
October 4, 2015 (Week 40)
No. of specimens tested 18,188 532,133
No. of positive specimens (%) 2,544 (14.0%) 53,564 (10.1%)
Positive specimens by type    
    Influenza A 1,481 (58.2%) 38,967 (72.7%)
    Influenza B 1,063 (41.8%) 14,597 (27.3%)
INFLUENZA Virus Isolated
View National and Regional Level Graphs and Data | View Chart Data | View Full Screen | View PowerPoint Presentation

The results of tests performed by public health laboratories, as well as the age group distribution of influenza positive tests, during the current week are summarized below.

  Week 14
Data Cumulative since
October 4, 2015 (Week 40)
No. of specimens tested 955 57,462
No. of positive specimens* 379 21,309
Positive specimens by type/subtype    
    Influenza A 240 (63.3%) 15,824 (74.3%)
          A(H1N1)pdm09 176 (73.3%) 12,821 (81.0%)
          H3 42 (17.5%) 2,750 (17.4%)
          Subtyping not performed 22 (9.2%) 253 (1.6%)
    Influenza B 139 (36.7%) 5,485 (25.7%)
           Yamagata lineage 52 (37.4%) 2,443 (44.5%)
           Victoria lineage 34 (24.5%) 1,023 (18.7%)
           Lineage not performed 53 (38.1%) 2,019 (36.8%)

*The percent of specimens testing positive for influenza is not reported because public health laboratories often receive samples that have already tested positive for influenza at a clinical laboratory and therefore percent positive would not be a valid indicator of influenza activity. Additional information is available at http://www.cdc.gov/flu/weekly/overview.htm.

INFLUENZA Virus Isolated
View National and Regional Level Graphs and Data | View Chart Data | View Full Screen | View PowerPoint Presentation

INFLUENZA Virus Isolated
View Chart Data | View Full Screen

INFLUENZA Virus Isolated
View Chart Data |View Full Screen

Influenza Virus Characterization:

CDC characterizes influenza viruses through one or more tests including genome sequencing, hemagglutination inhibition (HI) and/or neutralization assays. These data are used to compare how similar currently circulating influenza viruses are to the reference viruses used for developing influenza vaccines, and to monitor for changes in circulating influenza viruses. Historically, HI data have been used most commonly to assess the similarity between reference viruses and circulating viruses to suggest how well the vaccine may work until such time as vaccine effectiveness estimates are available. During the 2014–2015 season and to date, however, a portion of influenza A (H3N2) viruses do not yield sufficient hemagglutination titers for antigenic characterization by HI. For many of these viruses, CDC performs genetic characterization to determine the genetic group identity of those viruses. In this way, antigenic properties of these viruses can be inferred from viruses within the same genetic group that have been characterized antigenically.

CDC has characterized 1,604 influenza viruses [606 A (H1N1)pdm09, 411 A (H3N2), and 587 influenza B viruses] collected by U.S. laboratories since October 1, 2015.

Influenza A Virus [1,017]

Influenza B Virus [587]

2016-2017 Influenza Season – U.S. Influenza Vaccine Composition:

The World Health Organization (WHO) has recommended vaccine viruses for the 2016-2017 influenza season Northern Hemisphere vaccine composition, and the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has made the vaccine composition recommendation to be used in the United States. Both agencies recommend that trivalent vaccines contain an A/California/7/2009 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, and a B/Brisbane/60/2008-like (B/Victoria lineage) virus. It is recommended that quadrivalent vaccines, which have two influenza B viruses, contain the viruses recommended for the trivalent vaccines, as well as a B/Phuket/3073/2013-like (B/Yamagata lineage) virus. This represents a change in the influenza A (H3) component and a change in the influenza B lineage included in the trivalent vaccine compared with the composition of the 2015-2016 influenza vaccine. These vaccine recommendations were based on several factors, including global influenza virologic and epidemiologic surveillance, genetic characterization, antigenic characterization, antiviral resistance, and the candidate vaccine viruses that are available for production.

Antiviral Resistance:

Testing of influenza A(H1N1)pdm09, influenza A (H3N2), and influenza B virus isolates for resistance to neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) is performed at CDC using a functional assay. Additional influenza A(H1N1)pdm09 and influenza A (H3N2) clinical samples are tested for mutations of the virus known to confer oseltamivir resistance. The data summarized below combine the results of both testing methods. These samples are routinely obtained for surveillance purposes rather than for diagnostic testing of patients suspected to be infected with antiviral-resistant virus.

High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A(H1N1)pdm09 and influenza A (H3N2) viruses (the adamantanes are not effective against influenza B viruses). Therefore, data from adamantane resistance testing are not presented below.

Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2015






Virus Samples tested (n)

Resistant Viruses, Number (%)

Virus Samples tested (n)

Resistant Viruses, Number (%)

Virus Samples tested (n)

Resistant Viruses, Number (%)

Influenza A (H1N1)pdm09


11 (0.7)


0 (0.0)


11 (0.7)

Influenza A (H3N2)


0 (0.0)


0 (0.0)


0 (0.0)

Influenza B


0 (0.0)


0 (0.0)


0 (0.0)

The majority of recently circulating influenza viruses are susceptible to the neuraminidase inhibitor antiviral medications, oseltamivir, zanamivir, and peramivir; however, rare sporadic instances of oseltamivir-resistant and peramivir-resistant influenza A (H1N1)pdm09 viruses and oseltamivir-resistant influenza A (H3N2) viruses have been detected worldwide. Antiviral treatment as early as possible is recommended for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at high risk. for serious influenza-related complications. Additional information on recommendations for treatment and chemoprophylaxis of influenza virus infection with antiviral agents is available at http://www.cdc.gov/flu/antivirals/index.htm.

Pneumonia and Influenza (P&I) Mortality Surveillance:

Rapid tracking of pneumonia and influenza-associated deaths is done through two systems, the National Center for Health Statistics (NCHS) Mortality Surveillance System and the 122 Cities Mortality Reporting System. NCHS mortality surveillance data are presented by the week the death occurred and P&I percentages are released two weeks after the week of death to allow for collection of enough data to produce a stable P&I percentage. Users of the data should not expect the two systems to produce the same percentages, and the percent P&I deaths from each system should be compared to the corresponding system-specific baselines and thresholds.

NCHS Mortality Surveillance Data:

Based on NCHS mortality surveillance data available on April 14, 2016, 7.1% of the deaths occurring during the week ending March 26, 2016 (week 12) were due to P&I. This percentage is below the epidemic threshold of 7.5% for week 12.

Region and state-specific data are available at http://www.cdc.gov/flu/weekly/nchs.htm.

INFLUENZA Virus Isolated
View Regional and State Level Data | View Chart Data | View Full Screen | View PowerPoint Presentation

122 Cities Mortality Reporting System:

During week 14, 7.5% of all deaths reported through the 122 Cities Mortality Reporting System were due to P&I. This percentage was above the epidemic threshold of 7.1% for week 14.

Pneumonia And Influenza Mortality
View Full Screen | View PowerPoint Presentation

Influenza-Associated Pediatric Mortality:

Ten influenza-associated pediatric deaths were reported to CDC during week 14. Two deaths were associated with an influenza A (H1N1)pdm09 virus and occurred during weeks 11 and 13 (the weeks ending March 19 and April 2, 2016) and one death was associated with an influenza A (H3) virus and occurred during week 13. One death was associated with an influenza A virus for which no subtyping was performed and occurred during week 14 (the week ending April 9, 2016). Six deaths were associated with an influenza B virus and occurred during weeks 12 and 13 (the weeks ending March 26 and April 2, 2016).

A total of 50 influenza-associated pediatric deaths have been reported during the 2015-2016 season from Puerto Rico [1], Chicago [1], and 23 states (Arizona [3], California [9], Colorado [1], Florida [6], Illinois [1], Indiana [2], Louisiana [1], Maine [1], Maryland, [1], Massachusetts [2], Michigan [1], Minnesota [3], Mississippi [1], Nebraska [1], Nevada [3], New Jersey [1], New York [2], Ohio [1], Tennessee [2], Texas [3], Virginia [1], Washington [1], and Wisconsin [1]).

Additional data can be found at: http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html.

Click on image to launch interactive tool

View Interactive Application | View Full Screen | View PowerPoint Presentation

Influenza-Associated Hospitalizations:

The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) and adults (since the 2005-2006 influenza season).

The FluSurv-NET covers more than 70 counties in the 10 Emerging Infections Program (EIP) states (CA, CO, CT, GA, MD, MN, NM, NY, OR, and TN) and additional Influenza Hospitalization Surveillance Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance surveillance during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 2009-2010 season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; MI, OH, RI, and UT during the 2011-2012 season; IA, MI, OH, RI, and UT during the 2012-2013 season; and MI, OH, and UT during the 2013-2014, 2014-15 and 2015-16 seasons.

Data gathered are used to estimate age-specific hospitalization rates on a weekly basis, and describe characteristics of persons hospitalized with severe influenza illness. The rates provided are likely to be an underestimate as influenza-related hospitalizations can be missed, either because testing is not performed, or because cases may be attributed to other causes of pneumonia or other common influenza-related complications.

Between October 1, 2015 and April 9, 2016, 7,368 laboratory-confirmed influenza-associated hospitalizations were reported. The overall hospitalization rate was 26.6 per 100,000 population. The highest rate of hospitalization was among adults aged ≥65 years (69.6 per 100,000 population), followed adults aged 50-64 (38.6 per 100,000 population) and children aged 0-4 years (36.8 per 100,000 population). Among all hospitalizations, 5,741 (77.9%) were associated with influenza A, 1,553 (21.1%) with influenza B, 36 (0.5%) with influenza A and B co-infection, and 38 (0.5%) had no virus type information. Among those with influenza A subtype information, 1,737 (88.8%) were A(H1N1)pdm09 and 217 (11.1%) were A(H3N2) virus.

Clinical findings are preliminary and based on 1,578 (21.4%) cases with complete medical chart abstraction. The majority (91.3%) of hospitalized adults had at least one reported underlying medical condition; the most commonly reported were obesity, cardiovascular disease, metabolic disorders and chronic lung disease. There were 235 hospitalized children with complete medical chart abstraction; 129 (54.9%) had at least one underlying medical condition. The most commonly reported underlying medical conditions among pediatric patients were asthma and neurologic disorders. Among the 162 hospitalized women of childbearing age (15-44 years), 38 (23.5%) were pregnant.

Additional FluSurv-NET data can be found at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html and http://gis.cdc.gov/grasp/fluview/FluHospChars.html.

Click on graph to launch interactive tool

Data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based surveillance for influenza related hospitalizations in children and adults in 13 U.S. states. Cumulative incidence rates are calculated using the National Center for Health Statistics’ (NCHS) population estimates for the counties included in the surveillance catchment area.

View Interactive Application | View Full Screen | View PowerPoint Presentation

Click on graph to launch interactive tool2

FluSurv-NET data are preliminary and displayed as they become available. Therefore, figures are based on varying denominators as some variables represent information that may require more time to be collected. Data are refreshed and updated weekly. Asthma includes a medical diagnosis of asthma or reactive airway disease; Cardiovascular diseases include conditions such as coronary heart disease, cardiac valve disorders, congestive heart failure, and pulmonary hypertension; does not include isolated hypertension; Chronic lung diseases include conditions such as chronic obstructive pulmonary disease, bronchiolitis obliterans, chronic aspiration pneumonia, and interstitial lung disease; Immune suppression includes conditions such as immunoglobulin deficiency, leukemia, lymphoma, HIV/AIDS, and individuals taking immunosuppressive medications; Metabolic disorders include conditions such as diabetes mellitus; Neurologic diseases include conditions such as seizure disorders, cerebral palsy, and cognitive dysfunction; Neuromuscular diseases include conditions such as multiple sclerosis and muscular dystrophy; Obesity was assigned if indicated in patient's medical chart or if body mass index (BMI) >30 kg/m2; Pregnancy percentage calculated using number of influenza-positive females aged between 15 and 44 years of age as the denominator; Renal diseases include conditions such as acute or chronic renal failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine clearance; No known condition indicates that the person did not have any known high risk medical condition indicated in medical chart at the time of hospitalization.

View Interactive Application | View Full Screen | View PowerPoint Presentation

Outpatient Illness Surveillance:

Nationwide during week 14, 2.1% of patient visits reported through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like illness (ILI). This percentage is at the national baseline of 2.1%. (ILI is defined as fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.)

The increase in the percentage of patient visits for ILI in weeks 51 and 52 (the weeks ending December 26, 2015 and January 2, 2016) may be influenced in part by a reduction in routine healthcare visits during the holidays, as has occurred in previous seasons.

Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html.

national levels of ILI and ARI
View National and Regional Level Graphs and Data | View Chart Data | View Full Screen | View PowerPoint Presentation

On a regional level, the percentage of outpatient visits for ILI ranged from 1.5% to 2.9% during week 14. Six of 10 regions (Regions 1, 2, 3, 4, 8, and 10) reported a proportion of outpatient visits for ILI at or above their region-specific baseline levels.

ILINet State Activity Indicator Map:

Data collected in ILINet are used to produce a measure of ILI activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI and are compared to the average percent of ILI visits that occur during weeks with little or no influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity from outpatient clinics being below, or only slightly above, the average, to high, which would correspond to ILI activity from outpatient clinics being much higher than average.

During week 14, the following ILI activity levels were calculated:

Click on map to launch interactive tool


Click on map to launch interactive tool

*This map uses the proportion of outpatient visits to health care providers for ILI to measure the ILI activity level within a state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city could cause the state to display high activity levels.
Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the full picture of influenza activity for the whole state.
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data are received.
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists

The influenza activity reported by state and territorial epidemiologists indicates geographic spread of influenza viruses, but does not measure the severity of influenza activity.

During week 14, the following influenza activity was reported:

U. S. Map for Weekly Influenza Activity

Flu Activity data in XML Format | View Full Screen

View Full Screen

Additional National and International Influenza Surveillance Information

FluView Interactive: FluView includes enhanced web-based interactive applications that can provide dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications allow people to create customized, visual interpretations of influenza data, as well as make comparisons across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit http://www.cdc.gov/flu/weekly/fluviewinteractive.htm.

U.S. State and local influenza surveillance: Click on a jurisdiction below to access the latest local influenza information.









District of Columbia





















New Hampshire

New Jersey

New Mexico

New York

North Carolina

North Dakota





Rhode Island

South Carolina

South Dakota







West Virginia



New York City

Virgin Islands

Puerto Rico

World Health Organization: Additional influenza surveillance information from participating WHO member nations is available through FluNet and the Global Epidemiology Reports.

WHO Collaborating Centers for Influenza located in Australia, China, Japan, the United Kingdom, and the United States (CDC in Atlanta, Georgia).

Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and the European Centre for Disease Prevention and Control at http://www.flunewseurope.org/

Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at http://www.phac-aspc.gc.ca/fluwatch/

Public Health England: The most up-to-date influenza information from the United Kingdom is available at https://www.gov.uk/government/statistics/weekly-national-flu-reports

Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and none should be inferred. CDC is not responsible for the content of the individual organization web pages found at these links.

An overview of the CDC influenza surveillance system, including methodology and detailed descriptions of each data component, is available at: http://www.cdc.gov/flu/weekly/overview.htm.